No connection

Search Results

ALEC vs PROF

ALEC
Alector, Inc.
BEARISH
Price
$2.20
Market Cap
$242.8M
Sector
Healthcare
AI Confidence
85%
PROF
Profound Medical Corp.
BEARISH
Price
$6.65
Market Cap
$241.4M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ALEC
--
PROF
--
Forward P/E
ALEC
-2.22
PROF
-8.48
P/B Ratio
ALEC
7.91
PROF
3.63
P/S Ratio
ALEC
11.54
PROF
14.99
EV/EBITDA
ALEC
-0.16
PROF
-4.58

Profitability

Gross Margin
ALEC
0.0%
PROF
70.77%
Operating Margin
ALEC
-587.53%
PROF
-123.29%
Profit Margin
ALEC
0.0%
PROF
-264.44%
ROE
ALEC
-181.56%
PROF
-67.12%
ROA
ALEC
-25.13%
PROF
-34.91%

Growth

Revenue Growth
ALEC
-88.5%
PROF
43.1%
Earnings Growth
ALEC
--
PROF
--

Financial Health

Debt/Equity
ALEC
1.18
PROF
0.07
Current Ratio
ALEC
3.83
PROF
12.53
Quick Ratio
ALEC
3.68
PROF
11.02

Dividends

Dividend Yield
ALEC
--
PROF
--
Payout Ratio
ALEC
0.0%
PROF
0.0%

AI Verdict

ALEC BEARISH

ALEC's Advanced Deterministic Scorecard reveals significant financial distress: a Piotroski F-Score of 4/9 indicates weak operational health, and the absence of an Altman Z-Score (with a Debt/Equity of 1.18 and negative ROE/ROA) raises bankruptcy risk concerns. Despite a recent 1Y return of +53.9%, the stock trades at extreme valuation multiples (Price/Sales 11.54, Price/Book 7.91) with no profitability, negative earnings, and a staggering -88.5% YoY revenue decline. Insider selling of $0.49M over six months, including large sales by top executives, signals poor confidence. The analyst consensus of 'hold' reflects cautious optimism, but the fundamental deterioration and lack of sustainable value drivers suggest limited upside.

Strengths
Recent quarterly earnings have consistently beaten estimates (3/4 in last 4 quarters)
Average earnings surprise of 19.79% in the last four quarters indicates strong execution on guidance
High current and quick ratios (3.83 and 3.68) suggest strong short-term liquidity
Risks
Piotroski F-Score of 4/9 indicates weak financial health and operational stability
Negative ROE (-181.56%) and ROA (-25.13%) reflect severe capital inefficiency
Revenue has collapsed by 88.5% YoY, signaling fundamental business deterioration
PROF BEARISH

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company exhibits strong top-line momentum with 43.10% YoY revenue growth and a healthy gross margin of 70.77%, this is completely offset by a catastrophic profit margin of -264.44%. The company is essentially a high-burn growth play with a very expensive valuation (P/S of 14.99) and a long history of negative earnings. Only the exceptionally high current ratio (12.53) and low debt provide a temporary safety net against insolvency.

Strengths
Strong revenue growth (43.10% YoY, 61.32% Q/Q)
High gross margins (70.77%) typical of scalable medical devices
Very low leverage (Debt/Equity 0.07)
Risks
Severe operational inefficiency (Profit Margin -264.44%)
Critical fundamental health failure (Piotroski F-Score 1/9)
Extreme valuation premium (Price/Sales 14.99)

Compare Another Pair

ALEC vs PROF: Head-to-Head Comparison

This page compares Alector, Inc. (ALEC) and Profound Medical Corp. (PROF) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile